The introduction of Retatrutide ZPHC, at a strength of 120mg, is creating considerable interest within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication seems to provide impressive improvements in fat reduction compared to existing therapies. Preliminary research trials have demonstrated significant decreases in body